Thinking About Switching from Tirzepatide to Retatrutide?

Picture this: you've read about retatrutide and wondered whether your Mounjaro pen is already yesterday's news

It's a fair thing to wonder. Phase 2 data published in the New England Journal of Medicine showed retatrutide producing average weight reductions of around 17–24% over 48 weeks, depending on dose, figures that caught serious attention from researchers and patients alike. The mechanism adds a third receptor pathway (glucagon) on top of the GIP and GLP-1 signalling that tirzepatide already targets, which is why the results look different on paper.

But phase 2 is not the same as a licensed medicine. Retatrutide is still in phase 3 trials at the time of writing; the MHRA has not approved it, NICE has not appraised it, and no UK pharmacy (licensed or otherwise) can legally dispense it. If you see it offered online, that is a significant safety concern, not a shortcut. The MHRA's Yellow Card scheme is the right place to report suspect sellers.

A question our prescribers hear most weeks is some version of: "should I wait for something better?" The honest answer is that "better" is only meaningful once a medicine has completed trials, been assessed for safety in a real-world population, received regulatory approval and been appraised for clinical use. That process takes years. Tirzepatide has been through all of it.

What tirzepatide actually delivers, and where retatrutide trials currently stand

The comparison below uses verified figures. Tirzepatide data comes from the SURMOUNT-1 trial (2,539 adults, 72 weeks) and the NICE TA1026 appraisal. Retatrutide figures are phase 2 only and cannot be treated as a reliable prediction of a licensed product's performance.

Phase 2 trials recruit fewer participants over shorter periods than the large-scale programmes regulators require before approval. Retatrutide's early numbers are genuinely interesting to researchers; they are not yet a basis for clinical decisions about your treatment.

If tirzepatide isn't working well enough, here are the routes that exist right now

Not everyone reaches the weight-loss outcome they hoped for on a lower dose of tirzepatide, and there are legitimate things a prescriber can do about that. The licensed schedule runs from 2.5mg up to 15mg, with each step giving your system time to adjust before moving higher. If you have been on a stable dose for several months and progress has plateaued, your prescriber can review whether titrating upward is appropriate, provided there is clinical evidence of your current weight.

There are also other licensed options. Wegovy (semaglutide 2.4mg, or the newer 7.2mg dose approved by the MHRA in January 2026) is a GLP-1 receptor agonist with its own strong evidence base, and switching between GLP-1 class medicines is something prescribers consider when the clinical picture supports it. The direction of travel there is usually explored on its own terms rather than as a waiting strategy for an unlicensed treatment. Patients who have previously been on liraglutide may also want to read about how switching from liraglutide to tirzepatide works in practice, as the transition involves its own clinical considerations.

For more background on how tirzepatide compares to other authorised medicines, the retatrutide versus tirzepatide overview covers the trial landscape in detail, and our Mounjaro information page explains the licensed UK dose pathway fully. If you are already on tirzepatide and want to talk through your progress, our support team is available seven days a week.

How to switch if retatrutide becomes licensed in the future, and what the process would look like

Switching between injectable weight-loss medicines is not something to do without clinical oversight, whenever that question does become live. A prescriber would typically want to know your current dose, how long you have been stable on it, your response to treatment so far, and whether there is any clinical reason a different receptor profile might suit you better. There is no fixed washout period published for a tirzepatide-to-retatrutide switch in the way there is for, say, stopping an antidepressant, because the combination or sequencing has not been studied in approved clinical practice yet.

What that means practically: if retatrutide does receive MHRA authorisation and a NICE recommendation, the switch pathway will be defined by prescribing guidance at that point, not by today's speculation. The guide on switching from Mounjaro to retatrutide will be updated as the regulatory picture changes.

For now, the decision about which licensed medicine is right for you (and whether any change to your current regimen is warranted) is one that belongs in a clinical conversation. Check your eligibility to speak with one of our prescribers, or read more about the broader retatrutide versus Mounjaro evidence summary if you want the research context first. Which medicine suits your situation is a clinical decision our prescribers make with you.